EMVision expands pivotal emu brain scanner trial to include acute ischaemia detection

An announcement from EMvision Medical Devices Ltd. ( (AU:EMV) ) is now available.

EMVision is expanding the scope of its pivotal validation trial for the emu brain scanner to include acute ischaemia detection alongside haemorrhage detection, leveraging progress from a parallel Continuous Innovation study. This simultaneous validation is intended to streamline the regulatory pathway via an FDA De Novo route and broaden the device’s clinical utility and commercial appeal from its initial U.S. clearance.

Patient recruitment for the pivotal trial has surpassed 125 participants across leading stroke centres in the United States and Australia, with no device-related adverse events reported and recent initiatives expected to accelerate enrolment. The company is also advancing its emu Regional Benefit Study and has received further non-dilutive CRC-P funding, while preparing additional sites, including Princess Alexandra Hospital and potential new U.S. centres, to support full trial enrolment and subsequent regulatory submissions.

The most recent analyst rating on (AU:EMV) stock is a Buy with a A$3.15 price target. To see the full list of analyst forecasts on EMvision Medical Devices Ltd. stock, see the AU:EMV Stock Forecast page.

More about EMvision Medical Devices Ltd.

EMVision Medical Devices Ltd. is an Australian medtech company focused on non-invasive brain imaging solutions for time-critical conditions such as stroke. Its first-generation emu brain scanner is a point-of-care device designed to support earlier triage and treatment decisions at the bedside, and serves as the predicate platform for a second-generation portable First Responder scanner aimed at pre-hospital use.

Average Trading Volume: 44,818

Technical Sentiment Signal: Buy

Current Market Cap: A$177.3M

For detailed information about EMV stock, go to TipRanks’ Stock Analysis page.